<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969877</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2012-001879-37</org_study_id>
    <secondary_id>2012-001879-37</secondary_id>
    <nct_id>NCT01969877</nct_id>
  </id_info>
  <brief_title>A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.</brief_title>
  <acronym>ARTSCANIII</acronym>
  <official_title>A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint in this study is to investigate if there is a difference in overall&#xD;
      survival in patients with locally advanced head and neck cancer, randomized to either&#xD;
      radiotherapy and cetuximab or radiotherapy and cisplatin. A second randomization is performed&#xD;
      in patients with T3-T4 tumors; allocated radiotherapy either 68.0 Gy or 73.1 Gy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 3 month for 2 years, and every 6 month until 5 years for evaluation of overall survival</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Locally Advanced Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed , previous untreated head and neck squamous&#xD;
             cell cancer of the oral cavity, hypopharynx, larynx or of the oral cavity aimed for&#xD;
             unimodal treatment with radiotherapy with curative intent&#xD;
&#xD;
          -  Tumor stage III and IV , but no evidence of distant metastases beyond the regional&#xD;
             nodes in the neck&#xD;
&#xD;
          -  WHO/Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  The patient must be expected to withstand radiotherapy combined with cisplatin or&#xD;
             cetuximab&#xD;
&#xD;
          -  The patient must be able to understand the information about the treatment and give a&#xD;
             written informed concent to participate in the trial&#xD;
&#xD;
          -  Adequate follow-up study must be possible; this will exclude a patient who is&#xD;
             uncooperative&#xD;
&#xD;
          -  Adequate renal function, creatinine clearance over 50 ml/min/1.73 estimated according&#xD;
             to local practice at each study centre&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous malignant disease in the head and neck region, with exception for basal cell&#xD;
             carcinoma or curatively treated squamous cell carcinoma of the skin with follow-up&#xD;
             time of at least 3 years&#xD;
&#xD;
          -  Concomitant or previous malignancies. Exceptions are adequately treated basal cell&#xD;
             carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix&#xD;
             uteri, or other previous malignancy with a disease-free interval of at least 5 years&#xD;
&#xD;
          -  Two or more synchronous primary head and neck squamous cell cancer at time of&#xD;
             diagnosis&#xD;
&#xD;
          -  Co-existing disease prejudicing survival (expected survival less than 6 months)&#xD;
&#xD;
          -  Absolute neutrophil count less than 1.5 x 109/L&#xD;
&#xD;
          -  Platelet count less than 100 x 109/L&#xD;
&#xD;
          -  Bilirubin over 1.5 times upper limit of normal&#xD;
&#xD;
          -  Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) more than 3 times&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Allergy to study drug or to the excipients in their formulation&#xD;
&#xD;
          -  Neuropathy grade 2 or more according to Common terminology criteria for adverse events&#xD;
             (CTCAE) v.4.0&#xD;
&#xD;
          -  Hearing loss/tinnitus is a relative exclusion criteria; the responsible physician&#xD;
             decides whether the patient may be included in the study&#xD;
&#xD;
          -  Severe cardiac illness; myocardial infarction within 6 months prior to randomization,&#xD;
             severe congestive heart failure, severe cardiomyopathy, ventricular arrythmia,&#xD;
             unstable angina, uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Gebre-Medhin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital Ryhov</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universityhospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Västmanlands Hospital Västerås</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 16, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Human papilloma virus</keyword>
  <keyword>Health economy</keyword>
  <keyword>Biomarker investigations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

